ReviewTherapeutic advances in psychopharmacology2018
Assessment and management of sexual dysfunction in the context of depression.
Review in Therapeutic advances in psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 56 citations in OpenAlex.
- The association between depression, perceived stress, and sexual function among adults attending primary health care services.BMC public health · 2025Article
- A structural equation modelling to explore the determinants of mental health disorders among reproductive-aged women in Nepal: a nation-wide cross-sectional survey.BMC psychiatry · 2024Article
- Assessment of sexual beliefs among "drug naive male" patients attending psychiatry OPD in a teaching institution: A cross-sectional study.Journal of family medicine and primary care · 2024Article
- Urinary symptoms and female sexual dysfunction in women with type 1 diabetes: the role of depression.The journal of sexual medicine · 2023Article
- Talking about Sexuality in Stroke Individuals: The New Era of Sexual Rehabilitation.Journal of clinical medicine · 2023Article
- Sexuality, quality of life and psychological well-being in older adults: A correlational study.European journal of obstetrics & gynecology and reproductive biology: X · 2023Article
- Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability.Neuroscience applied · 2023Review
- Questions in psychiatry (QuiP): Assessing sexual well-being.Bipolar disorders · 2022Article
- Individualized identification of sexual dysfunction of psychiatric patients with machine-learning.Scientific reports · 2022Article
- Use of Sertraline in Hemodialysis Patients.Medicina (Kaunas, Lithuania) · 2021Review
- Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update.Therapeutic advances in psychopharmacology · 2021Review
- Evaluating co-occurrence of depression and sexual dysfunction and related factors among Iranian rural women: A population-based study.BioMedicine · 2020Article
- Prevalence of antidepressant-induced sexual dysfunction among psychiatric outpatients attending a tertiary care hospital.Neurosciences (Riyadh, Saudi Arabia) · 2020Article
- What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?Therapeutic advances in psychopharmacology · 2019Review
- Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX). Separating the effects of the disorder from those of medications is challenging; we present a concise, evidence-based schematic to assist physicians in minimizing treatment-emergent sexual dysfunction (TESD) while treating depression. Vascular, hormonal, neurogenic, and pharmacological factors should be considered when a patient presents with SD. We also recommend that physicians obtain patient information about baseline and historical sexual functioning before prescribing a drug that may lead to SD and follow up accordingly. When the goal is to treat depression while attenuating the risk of sexual symptoms, physicians may wish to consider agomelatine, bupropion, desvenlafaxine, moclobemide, trazodone, vilazodone, and vortioxetine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.